PL3983402T4 - Pochodne 1-((s)-1-(3-chloro-5-fluoro-2-((4-(1h-pirazol-1-ilo)-2-metylochinolin-8-yloksy)metylo)fenylo)etylo)imidazolidyno-2,4-dionu i związki pokrewne jako antagoniści receptora bradykininy (bk) b2 do leczenia chorób skóry - Google Patents
Pochodne 1-((s)-1-(3-chloro-5-fluoro-2-((4-(1h-pirazol-1-ilo)-2-metylochinolin-8-yloksy)metylo)fenylo)etylo)imidazolidyno-2,4-dionu i związki pokrewne jako antagoniści receptora bradykininy (bk) b2 do leczenia chorób skóryInfo
- Publication number
- PL3983402T4 PL3983402T4 PL20732502.8T PL20732502T PL3983402T4 PL 3983402 T4 PL3983402 T4 PL 3983402T4 PL 20732502 T PL20732502 T PL 20732502T PL 3983402 T4 PL3983402 T4 PL 3983402T4
- Authority
- PL
- Poland
- Prior art keywords
- methylquinolin
- bradykinin
- imidazolidine
- yloxy
- pyrazol
- Prior art date
Links
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 title 2
- 101800004538 Bradykinin Proteins 0.000 title 1
- RIDCMUVIHWSNNV-HNNXBMFYSA-N ClC=1C(=C(C=C(C=1)F)[C@H](C)N1C(NC(C1)=O)=O)COC=1C=CC=C2C(=CC(=NC=12)C)N1N=CC=C1 Chemical class ClC=1C(=C(C=C(C=1)F)[C@H](C)N1C(NC(C1)=O)=O)COC=1C=CC=C2C(=CC(=NC=12)C)N1N=CC=C1 RIDCMUVIHWSNNV-HNNXBMFYSA-N 0.000 title 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 title 1
- 102100035792 Kininogen-1 Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 208000017520 skin disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19176207 | 2019-05-23 | ||
| PCT/EP2020/064375 WO2020234479A1 (en) | 2019-05-23 | 2020-05-25 | 1-((s)-1-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)ethyl)-imidazolidine-2,4-dione derivatives and related compounds as bradykinin (bk) b2 receptor antagonist for treating skin diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL3983402T3 PL3983402T3 (pl) | 2024-04-02 |
| PL3983402T4 true PL3983402T4 (pl) | 2024-04-02 |
Family
ID=66668713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20732502.8T PL3983402T4 (pl) | 2019-05-23 | 2020-05-25 | Pochodne 1-((s)-1-(3-chloro-5-fluoro-2-((4-(1h-pirazol-1-ilo)-2-metylochinolin-8-yloksy)metylo)fenylo)etylo)imidazolidyno-2,4-dionu i związki pokrewne jako antagoniści receptora bradykininy (bk) b2 do leczenia chorób skóry |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12312330B2 (pl) |
| EP (1) | EP3983402B1 (pl) |
| JP (1) | JP7462683B2 (pl) |
| CN (1) | CN113906018B (pl) |
| AR (1) | AR118982A1 (pl) |
| AU (1) | AU2020280924B2 (pl) |
| ES (1) | ES2962971T3 (pl) |
| MX (1) | MX2021014288A (pl) |
| PL (1) | PL3983402T4 (pl) |
| TW (1) | TWI827847B (pl) |
| UY (1) | UY38706A (pl) |
| WO (1) | WO2020234479A1 (pl) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680870B2 (en) | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| ES2218554T3 (es) * | 1994-10-27 | 2004-11-16 | Fujisawa Pharmaceutical Co., Ltd. | Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina. |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| DE19612067A1 (de) | 1996-03-27 | 1997-10-02 | Hoechst Ag | Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen |
| AUPN952696A0 (en) * | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| AU6422098A (en) * | 1997-03-24 | 1998-10-20 | Kyowa Hakko Kogyo Co. Ltd. | Benzene derivatives |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| JP2002517461A (ja) | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | ブラジキニンアンタゴニスト |
| HUP0104110A3 (en) | 1998-10-21 | 2003-01-28 | Astellas Pharma Inc Chuo Ku | Vitreous form of known bradykinin antagonist and medicament containing it |
| FR2790260B1 (fr) * | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
| GB9913079D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| AU2001229580A1 (en) | 2000-01-18 | 2001-08-14 | Nuerogen Corporation | Substituted imidazoles as selective modulators of bradykinin b2 receptors |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| JP2005525398A (ja) | 2002-04-10 | 2005-08-25 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体 |
| EP1914236A1 (en) * | 2002-04-10 | 2008-04-23 | Ortho-McNeil Pharmaceutical, Inc. | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
| ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) * | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| EP1741444A1 (en) | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR068509A1 (es) * | 2007-09-19 | 2009-11-18 | Jerini Ag | Antagosnistas del receptor de bradiquinina b1 |
| AR073304A1 (es) * | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| WO2014159637A1 (en) * | 2013-03-14 | 2014-10-02 | Shire Human Genetic Therapies, Inc. | Methods of treating b2-bradykinin receptor mediated angioedema |
| AR113839A1 (es) * | 2017-11-24 | 2020-06-17 | Pharvaris B V | Antagonistas del receptor b2 de bradiquinina |
| AR118983A1 (es) * | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
-
2020
- 2020-05-21 UY UY0001038706A patent/UY38706A/es active IP Right Grant
- 2020-05-21 AR ARP200101443A patent/AR118982A1/es unknown
- 2020-05-22 TW TW109117162A patent/TWI827847B/zh active
- 2020-05-25 WO PCT/EP2020/064375 patent/WO2020234479A1/en not_active Ceased
- 2020-05-25 US US17/530,967 patent/US12312330B2/en active Active
- 2020-05-25 PL PL20732502.8T patent/PL3983402T4/pl unknown
- 2020-05-25 JP JP2021569938A patent/JP7462683B2/ja active Active
- 2020-05-25 ES ES20732502T patent/ES2962971T3/es active Active
- 2020-05-25 MX MX2021014288A patent/MX2021014288A/es unknown
- 2020-05-25 EP EP20732502.8A patent/EP3983402B1/en active Active
- 2020-05-25 CN CN202080038066.3A patent/CN113906018B/zh active Active
- 2020-05-25 AU AU2020280924A patent/AU2020280924B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3139229A1 (en) | 2020-11-26 |
| JP2022534389A (ja) | 2022-07-29 |
| CN113906018A (zh) | 2022-01-07 |
| UY38706A (es) | 2020-12-31 |
| AR118982A1 (es) | 2021-11-17 |
| EP3983402C0 (en) | 2023-08-16 |
| WO2020234479A1 (en) | 2020-11-26 |
| TW202110429A (zh) | 2021-03-16 |
| JP7462683B2 (ja) | 2024-04-05 |
| PL3983402T3 (pl) | 2024-04-02 |
| MX2021014288A (es) | 2022-01-06 |
| EP3983402B1 (en) | 2023-08-16 |
| US20220135542A1 (en) | 2022-05-05 |
| AU2020280924B2 (en) | 2023-07-27 |
| AU2020280924A1 (en) | 2021-11-25 |
| EP3983402A1 (en) | 2022-04-20 |
| US12312330B2 (en) | 2025-05-27 |
| TWI827847B (zh) | 2024-01-01 |
| ES2962971T3 (es) | 2024-03-22 |
| CN113906018B (zh) | 2024-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ597647A (en) | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
| IL281196A (en) | Process for the preparation of methyl 6-(4,2-dichlorophenyl)-5-[4-[(S3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-H7-benzo[ 7]Anolene-2-carboxylate | |
| RU2223116C2 (ru) | Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p | |
| MX2025013698A (es) | Una 7-h-pirrolo[2,3-d]pirimidina inhibidora de jak | |
| MY199103A (en) | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists | |
| PH12012500809A1 (en) | Methods and compositions for treating cancer | |
| MX2020005818A (es) | Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa). | |
| ATE534632T1 (de) | Thiazole, imidazole und pyrazole als proteinkinasehemmer | |
| NO20090580L (no) | Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer | |
| NO20072443L (no) | Fungicide aktive ingredienskombinasjoner | |
| NZ597595A (en) | Heterocyclic compounds and uses therof | |
| DK3724191T3 (da) | 5-(2-(2,5-difluorphenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazol[1,5-a]pyrimidinderivater og lignende forbindelser som trk-kinasehæmmere til cancerbehandling | |
| WO2009024823A3 (en) | Cyclopropyl amide derivatives | |
| DK2709990T3 (da) | 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedionderivater som PARP-hæmmere til behandling af cancer | |
| WO2006054143A8 (en) | Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine | |
| ATE402697T1 (de) | 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität | |
| PL3956326T3 (pl) | Pochodne (r)-3-(3-chloro-5-fluoro-2-((4-(1h-pirazol-1-ilo)-2-metylochinolin-8-yloksy)metylo)fenylo)morfoliny i związki pokrewne jako antagonista receptora bradykininy (bk) b2 do leczenia chorób skóry | |
| WO2008072190A3 (en) | Compositions of azimilide dihydrochloride | |
| EP3837244C0 (en) | 1-METHYL-4-[(4-PHENYLPHENYL)SULFONYLMETHYL]CYCLOHEXYANOL AND 1-METHYL-4-[[4-(2-PYRIDYL)PHENYL]SULFONYLMETHYL]CYCLOHEXANOL COMPOUNDS AND THEIR THERAPEUTIC USE | |
| CL2018003107A1 (es) | Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo | |
| NZ612221A (en) | Ectoparasiticidal active substance combinations | |
| NZ623384A (en) | Antimicrobial compounds and methods of making and using the same | |
| SG11201707863QA (en) | Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate | |
| PL3983402T4 (pl) | Pochodne 1-((s)-1-(3-chloro-5-fluoro-2-((4-(1h-pirazol-1-ilo)-2-metylochinolin-8-yloksy)metylo)fenylo)etylo)imidazolidyno-2,4-dionu i związki pokrewne jako antagoniści receptora bradykininy (bk) b2 do leczenia chorób skóry | |
| IL276223A (en) | History of triazole, imidazole, and pyrrole fused piperazines and their use as modulators of mGlu5 receptors |